Questions and controversies in innate immune research: what is the physiological role of NLRP3?

Cell Death Discovery

Volumn 2, Issue 1, 2016, Pages

  Coll, Rc ^a   O’Neill, Laj ^b   Schroder, K ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85012150662     PISSN: None     EISSN: 20587716     Source Type: Journal    
DOI: 10.1038/cddiscovery.2016.19     Document Type: Review

References (42)

1. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 301–305.
2. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821–832.
3. Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol 2015; e-pub ahead of print 9 November 201510.1038/cmi.2015.95.
4. Chen KW, Schroder K. Antimicrobial functions of inflammasomes. Curr Opin Microbiol 2013; 16: 311–318.
5. Clay GM, Sutterwala FS, Wilson ME. NLR proteins and parasitic disease. Immunol Res 2014; 59: 142–152.
6. Karki R, Man SM, Malireddi RK, Gurung P, Vogel P, Lamkanfi M et al. Concerted activation of the AIM2 and NLRP3 inflammasomes orchestrates host protection against Aspergillus infection. Cell Host Microbe 2015; 17: 357–368.
7. Gorfu G, Cirelli KM, Melo MB, Mayer-Barber K, Crown D, Koller BH et al. Dual role for inflammasome sensors NLRP1 and NLRP3 in murine resistance to Toxoplasma gondii. MBio 2014; 5: pii: e01117-13.
8. Broz P, Newton K, Lamkanfi M, Mariathasan S, Dixit VM, Monack DM. Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J Exp Med 2010; 207: 1745–1755.
9. Broz P, Ruby T, Belhocine K, Bouley DM, Kayagaki N, Dixit VM et al. Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature 2012; 490: 288–291.
10. Cunha LD, Zamboni DS. Subversion of inflammasome activation and pyroptosis by pathogenic bacteria. Front Cell Infect Microbiol 2013; 3: 76.
11. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 2015; 21: 677–687.
12. Youm YH, Grant RW, McCabe LR, Albarado DC, Nguyen KY, Ravussin A et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab 2013; 18: 519–532.
13. Haneklaus M, O'Neill LA. NLRP3 at the interface of metabolism and inflammation. Immunol Rev 2015; 265: 53–62.
14. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408–415.
15. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179–188.
16. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237–241.
17. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357–1361.
18. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010; 11: 897–904.
19. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095–2147.
20. Maedler K, Schumann DM, Sauter N, Ellingsgaard H, Bosco D, Baertschiger R et al. Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes 2006; 55: 2713–2722.
21. Spinas GA, Mandrup-Poulsen T, Molvig J, Baek L, Bendtzen K, Dinarello CA et al. Low concentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans. Acta Endocrinol (Copenh) 1986; 113: 551–558.
22. McCarthy DO, Kluger MJ, Vander AJ. Suppression of food intake during infection: is interleukin-1 involved? Am J Clin Nutr 1985; 42: 1179–1182.
23. Kotas ME, Jurczak MJ, Annicelli C, Gillum MP, Cline GW, Shulman GI et al. Role of caspase-1 in regulation of triglyceride metabolism. Proc Natl Acad Sci USA 2013; 110: 4810–4815.
24. Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 2006; 12: 650–656.
25. Murphy AJ, Kraakman MJ, Kammoun HL, Dragoljevic D, Lee MK, Lawlor KE et al. IL-18 Production from the NLRP1 inflammasome prevents obesity and metabolic syndrome. Cell Metab 2015; 23: 155–164.
26. Riera CE, Dillin A. Tipping the metabolic scales towards increased longevity in mammals. Nat Cell Biol 2015; 17: 196–203.
27. McGillicuddy FC, Harford KA, Reynolds CM, Oliver E, Claessens M, Mills KH et al. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 2011; 60: 1688–1698.
28. Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci USA 2011; 108: 15324–15329.
29. Okin D, Medzhitov R. Evolution of inflammatory diseases. Curr Biol 2012; 22: R733–R740.
30. Denes A, Lopez-Castejon G, Brough D. Caspase-1: is IL-1 just the tip of the ICEberg? Cell Death Dis 2012; 3: e338.
31. Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, Li Y et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 2011; 17: 1359–1372.
32. Zambetti LP, Mortellaro A. NLRPs, microbiota, and gut homeostasis: unravelling the connection. J Pathol 2014; 233: 321–330.
33. Bruchard M, Rebe C, Derangere V, Togbe D, Ryffel B, Boidot R et al. The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat Immunol 2015; 16: 859–870.
34. Coll RC, Robertson AA, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015; 21: 248–255.
35. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013; 25: 496–84.
36. Gross O, Poeck H, Bscheider M, Dostert C, Hannesschlager N, Endres S et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 2009; 459: 433–436.
37. Terlizzi M, Casolaro V, Pinto A, Sorrentino R. Inflammasome: cancer's friend or foe? Pharmacol Ther 2014; 143: 24–33.
38. Dupaul-Chicoine J, Arabzadeh A, Dagenais M, Douglas T, Champagne C, Morizot A et al. The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity 2015; 43: 751–763.
39. Paugh SW, Bonten EJ, Savic D, Ramsey LB, Thierfelder WE, Gurung P et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat Genet 2015; 47: 607–614.
40. Goto M. Inflammaging (inflammation+aging): a driving force for human aging based on an evolutionarily antagonistic pleiotropy theory? Biosci Trends 2008; 2: 218–230.
41. Bae JY, Park HH. Crystal structure of NALP3 protein pyrin domain (PYD) and its implications in inflammasome assembly. J Biol Chem 2011; 286: 39528–39536.
42. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13: 397–411.